Compound and method for treatment of movement disorders

Abstract

The disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids to subjects in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.

What claimed is: 
     
         1 . An emulsion, a tablet or a capsule comprising of pharmacologically inactive two or more components select from the group consisting of at least some hydrogen peroxide, at least some cannabinol, oil, micelles, phospholipids, and further consisting essentially of pharmacologically active isolated tetrahydrocannabinol (THC) isomers where (−)-Δ9-trans-THC isomer is at least 80% by mass of the total THC, and isolated cannabidiol (CBD) in the ratio of 1 THC and 2 CBD or 1 THC and 4 CBD by mass, and where the composition is stable for at least 12 months such that at least 89% by mass of (−)-Δ9-trans-THC remains in an undegraded form after the exposure to storage conditions with the ambient temperature of 20° C. and relative humidity of 55%, and where the composition is used for treating pain in subjects in need thereof. 
     
     
         2 . An emulsion or a capsule consisting essentially of:
 a) two or more selected from the group consisting of: gelatin, hypromellose, pullulan, cellulose, carrageenan, polyethylene glycol, tocopherol, benzalkonium chloride, chlorobutanol, thiomersal, butylated hydroxy anisole, butylated hydroxytoluene, polysorbate, sorbitol, sorbitan, sorbitan monolaurate, sorbitan monostearate, sorbitan tristearate, glycerol monostearate, glycerol monolaurate, decyl glucoside, lauryl glucoside, octyl glucoside, amine oxide, octaethylene glycol monododecyl ether, pentaethylene glycol monododecyl ether, sodium alginate, polyoxypropylene, polyoxyethylene, polyoxyethylene cetylether, glycerol ester, glycerol, glyceride, xanthan gum, arabic gum, castor wax, candelila wax, chitosan, polyhydroxy aldehyde, polyhydroxy ketone, propylene glycol monolaurate, caprylic/capric/diglyceryl succinate, methyl paraben, ethyl paraben, propyl paraben, poloxamer, tristearin, glycerol behenate, stearic acid, cholesterol, cetyl palmitate, poly(lactic-co-glycolic acid), poly-e-caprolactone, phosphatidylcholine, phosphatidylethanolamine, sorbitan monooleate, glyceryl tridecanoate, lecithin, ethyl lactate, tricaprylin, glyceryl palmitostearate, hyaluronic acid, boswellic acid, oleic acid, silica, saline, ethanol, sodium glycocholate, dimethyl-beta-cyclodextrin, carboxymethyl cellulose, starch, cremophor, piperine, curcumin, resveratrol, phylloquinone, menadione, sodium deoxycholate, glyceryl dibehenate, either cetyl palmitate, dipalmitoylphosphatidylcholine, pyridoxal 5-phosphate, linalool, palmitoylethanolamide, beta myrcene, magnesium, d-limolene, lactoferril, bakutrol, tetrahydro-curcumin, sea buckthorn, deanol, kinetin, vitamin K2, carnosine, ascorbyl pal-mitate, alpha lipoic acid, sulbutiamine, pterostilbene, green tea extract, sulfurophane, selenium.   b) a component selected from the group consisting of turpentine oil, soybean oil, sesame oil, castor oil, peanut oil, palm oil, orange oil, olive oil, nutmeg oil,  Mentha spicata  oil, lime oil, lemon oil, lavender oil, lanolin oil, cottonseed oil, sunflower oil, corn oil, eucalyptus oil, coriander oil, coconut oil, clove oil, cinnamon oil, apricot kernel oil, anis oil, peppermint oil, arachis oil, jojoba oil, argan oil, almond oil, cannabinol, polymerized siloxane, polyoxyethylene hydrogenated castor oil, pomegranate oil, polyethoxylated castor oil, mentha arvensis leaf oil, and mixtures thereof;   c) an isolated THC, where (−)-Δ9-trans-THC isomer is at least 80% by mass of the total THC, and isolated CBD in the ratio of 1 THC and 2 CBD or 1 THC and 4 CBD by mass; and   d) wherein the emulsion or capsule is stable for at least 12 months such that at least 89% by mass of the emulsion or capsule remains in undegraded form after exposure to storage conditions with an ambient temperature of about 25° C. and a relative humidity of about 55%.   
     
     
         3 . The dosage forms of  claims 1  and  2 , containing one or more select from the group consisting of water, emulsifier, lubricant, preservative, glidant, disintegrant, coloring agent, release retarding agent, binding agent, compression aid, granulating agent, coating or film agent, stabilizing agent, diluting agent, solvent, degradation product and/or impurity of the pharmacologically active or inactive components. 
     
     
         4 . The dosage forms of  claims 1  and  2 , containing one or more release-controlling polymers or one or more release-accelerating polymers, micro-emulsion or nano-emulsion, or a combination thereof. 
     
     
         5 . The dosage forms of  claims 1  and  2 , containing particles having a size that ranges from about 0.3 μm to about 1500 μm, diameter. 
     
     
         6 . The dosage forms of  claim 1 , containing one or more components selected from the group consisting of turpentine oil, soybean oil, sesame oil, castor oil, peanut oil, palm oil, orange oil, olive oil, nutmeg oil,  Mentha spicata  oil, lime oil, lemon oil, lavender oil, lanolin oil, cottonseed oil, sunflower oil, corn oil, eucalyptus oil, coriander oil, coconut oil, clove oil, cinnamon oil, apricot kernel oil, anis oil, peppermint oil, arachis oil, jojoba oil, almond oil, cannabinol, polymerized siloxane and mixtures thereof. 
     
     
         7 . The dosage forms of  claims 1  and  2 , containing one or more component selected from the group consisting of micelles, liposomes, microspheres, dendrimers, pro-nano-liposphere, piperine-pro-nano-liposphere, and nanoparticles. 
     
     
         8 . The dosage forms of  claims 1  and  2 , where THC is synthetic or extracted from a  Cannabis sativa  plant and purified to at least 70% by peak area HPLC. 
     
     
         9 . The tablet of  claim 1  for sublingual administration. 
     
     
         10 . The emulsion of  claims 1  and  2 , where the emulsion is a transdermal dosage form select from the group consisting of a transdermal patch, microneedle patch, a transdermal cream, a transdermal lotion, and a transdermal ointment, or where the emulsion is packaged in a dosage form for oral, intranasal, inhalation, parenteral, transdermal, rectal, vaginal, buccal, and sublingual administration. 
     
     
         11 . The dosage forms of  claims 1  and  2 , used for treating or preventing neuropathic pain, acute pain, chronic pain, or depression.